Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVT 302 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | EVT 302, 5 mg once Daily |
| 2 | PLACEBO_COMPARATOR | Placebo once daily |
| 3 | EXPERIMENTAL | EVT 302 plus open label Nicotine replacement |
| 4 | ACTIVE_COMPARATOR | Placebo plus nicotine replacement therapy |
| Name | Type | Description |
|---|---|---|
| EVT 302 | DRUG | EVT 302 5 mg once daily |
| Placebo | DRUG | Placebo to match EVT 302, 5 mg |
| EVT 302 plus open label Nicotine replacement | DRUG | Double-blind EVT 302 plus open label nicotine replacement |
| Placebo plus open label Nicotine Replacement | DRUG | Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily. |
| EVT 302, 10 mg | DRUG | 2 X EVT 302, 5 mg tablets |
| Nicotine replacement therapy (NRT) | DRUG | NRT patch containing 21 mg of nicotine |
| NRT placebo | DEVICE | Medically inert plaster cut to match the NRT plaster |
Inclusion Criteria: * Smoker of at least 10 cigarettes daily * Motivated to quit smoking * Reports at least one unsuccessful attempt to quit in the last 2 years * In generally good health * Provides written informed consent to participate in the sudy Exclusion Criteria: * Pregnant or nursing fema...
EVT 302 is an investigational small molecule developed by Evotec SE for smoking cessation. It has been studied in Phase 2 clinical trials in Germany, including a placebo-controlled study of 400 participants and a smaller study of 90 male smokers. It is not described as an approved product.
EVT 302 is being studied for smoking cessation, the therapeutic area of psychiatry. Its clinical program evaluated the drug in adults aged 18 and older who smoke, including a Phase 2 trial testing its effectiveness in quitting and a study of craving and withdrawal in cigarette-deprived male smokers.
EVT 302 is developed by Evotec SE, which trades under the ticker EVO. The company sponsored the Phase 2 smoking cessation studies of the compound conducted in Germany.
EVT 302 is in Phase 2 development. Both of its recorded trials are Phase 2 studies and both are completed, with no active trials currently listed. It is an investigational drug and is not described as FDA approved.
EVT 302 has been evaluated in two completed Phase 2 trials: NCT00738595, a placebo-controlled study of 400 participants testing effectiveness in smoking cessation, and NCT00622752, a 90-participant study in healthy male smokers examining craving and withdrawal with or without nicotine replacement therapy. Both were conducted in Germany.